Cargando…
12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108146/ http://dx.doi.org/10.1016/S0016-5085(21)02523-3 |
| _version_ | 1783690075233583104 |
|---|---|
| author | Chen, Shu-Ling Liu, Lijuan Liao, Changyi Hu, Huanjing Xie, Yubin Peng, Sui Kuang, Ming |
| author_facet | Chen, Shu-Ling Liu, Lijuan Liao, Changyi Hu, Huanjing Xie, Yubin Peng, Sui Kuang, Ming |
| author_sort | Chen, Shu-Ling |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8108146 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81081462021-05-10 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY Chen, Shu-Ling Liu, Lijuan Liao, Changyi Hu, Huanjing Xie, Yubin Peng, Sui Kuang, Ming Gastroenterology AASLD Abstracts AGA Institute. Published by Elsevier Inc. 2021-05 2021-05-10 /pmc/articles/PMC8108146/ http://dx.doi.org/10.1016/S0016-5085(21)02523-3 Text en Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AASLD Abstracts Chen, Shu-Ling Liu, Lijuan Liao, Changyi Hu, Huanjing Xie, Yubin Peng, Sui Kuang, Ming 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title | 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title_full | 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title_fullStr | 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title_full_unstemmed | 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title_short | 12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY |
| title_sort | 12 multifocal intrahepatic cholangiocarcinoma: immunogenomic and epigenomic heterogeneities influence the responses to targeted therapy and immunotherapy |
| topic | AASLD Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108146/ http://dx.doi.org/10.1016/S0016-5085(21)02523-3 |
| work_keys_str_mv | AT chenshuling 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT liulijuan 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT liaochangyi 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT huhuanjing 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT xieyubin 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT pengsui 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy AT kuangming 12multifocalintrahepaticcholangiocarcinomaimmunogenomicandepigenomicheterogeneitiesinfluencetheresponsestotargetedtherapyandimmunotherapy |